Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial. (8th February 2022)

• Record Type: Journal Article
• Authors: Ebata, Satoshi; Oba, Koji; Kashiwabara, Kosuke; Ueda, Keiko; Uemura, Yukari; Watadani, Takeyuki; Fukasawa, Takemichi; Miura, Shunsuke; Yoshizaki-Ogawa, Asako; Yoshihide, Asano; Yoshizaki, Ayumi; Sato, Shinichi
• Is Part Of: Rheumatology. Volume 61:Number 11(2022)
• Page Start: 4364
• Page End: 4373
• Publication Date: 2022-02-08
• Subjects: systemic sclerosis -- rituximab -- modified Rodnan skin score -- machine learning; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/keac023
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Objectives: The double-blind, parallel-group comparison, investigators initiated phase II clinical trial of IDEC-C2B8 (Rituximab) in patients with Systemic sclerosis (DesiReS) trial showed that rituximab is effective in treating skin sclerosis in SSc. However, which patient groups are likely to benefit from rituximab is unknown. Methods: We performed post-hoc analysis of prospective data from 54 patients who received rituximab or placebo in the DesiReS trial. Twenty-seven baseline factors were used to investigate subpopulations with different magnitudes of rituximab effect on modified Rodnan skin score (mRSS) change at 24 weeks. Based on a machine-learning algorithm called the causal tree, we explored the combination of predictors needed to identify subpopulations that would respond to rituximab and have good treatment outcomes. Results: Three factors were identified as branches of the decision tree: peripheral blood CD19-positive cell counts', 'mRSS', and 'serum surfactant protein D (SP-D) levels'. It was only in the subpopulation of patients with CD19-positive cell counts of <57/μl that rituximab did not show a significant improvement in mRSS vs placebo. In the subpopulation of patients with CD19-positive cell counts of ≥57/μl and mRSS ≥ 17, mRSS was most improved with rituximab [difference −17.06 (95% CI: −24.22, −9.89)]. The second greatest improvement in mRSS with rituximab was in the subpopulation with CD19-positive cell counts of ≥57/μl, mRSS < 17, and serum SP-D levels of ≥151 ng/ml [difference −10.35 (95% CI: −14.77, −5.93)]. Conclusion: SSc patients who have high CD19-positive cell counts and high mRSS are expected to have greater improvement in mRSS with rituximab. When the patients with high CD19-positive cell counts show low mRSS, serum SP-D levels may modify the treatment effect. Trial registration: ClinicalTrials.gov, https://clinicaltrials.gov, NCT04274257 and UMIN-CTR; https://center6.umin.ac.jp, UMIN000030139.